The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone, please call the Myeloma Infoline on 0800 980 3332
Last update: 11/07/2024
There are currently 37 open trials.
In 141 locations
What is a Clinical Trial?
There are currently 37 open trials
- Ide-cel CAR-T cell treatment with lenalidomide maintenance for newly diagnosed myeloma (KarMMa-9)
- Talquetamab combination treatments for myeloma (MonumenTAL-6)
- PET scans for diagnosing cardiac AL amyloidosis (CArdiag)
- Iberdomide maintenance for patients with newly diagnosed myeloma (EXCALIBER-Maintenance)
- Effectiveness of linvoseltamab for relapsed and/or refractory myeloma (LINKER-MM3)
- Belantamab as monotherapy or in combination with other treatments for myeloma (DREAMM-20)
- ABBV-453 for relapsed or refractory myeloma
- ABBV-383 for relapsed and/or refractory myeloma
- Teclistamab monotherapy for relapsed and/or refractory myeloma (MajesTEC-9)
- Iopofosine I 131 (CLR 131) for patients with B-cell malignancies, including myeloma (CLOVER-1)
- SAR445514 for relapsed/refractory myeloma and relapsed/refractory AL amyloidosis
- BGB-11417 for relapsed/refractory myeloma
- Daratumumab-based treatments for AL amyloidosis (AQUARIUS)
- CC-92480, carfilzomib, and dexamethasone (480Kd) for the treatment of relapsed and/or refractory myeloma (SUCCESSOR-2)
- JNJ-79635322 for relapsed and/or refractory myeloma or AL amyloidosis
- Mezigdomide, bortezomib, and dexamethasone (480Vd) for the treatment of relapsed and/or refractory myeloma (SUCCESSOR-1)
- Talquetamab combination treatments for myeloma (MonumenTAL-3)
- Iberdomide, daratumumab and dexamethasone (IberDd) for the treatment of relapsed and/or refractory myeloma (EXCALIBER-RRMM)
- A study evaluating vemurafenib and cobimetinib for the treatment of myeloma patients (DETERMINE)
- Forimtamig for relapsed and/or refractory myeloma
- Teclistamab in combination with daratumumab, lenalidomide, and talquetamab for newly diagnosed myeloma (MajesTEC-7)
- Birtamimab in AL amyloidosis patients (Mayo stage IV) (AFFIRM-AL)
- Escalating doses of REGN5458 for relapsed and/or refractory myeloma
- Talquetamab combination treatments for myeloma (MonumenTAL-2)
- DTP3 for relapsed and/or refractory myeloma
- Cevostamab for relapsed and/or refractory myeloma (CAMMA 1)
- Belantamab mafodotin for relapsed and/or refractory myeloma (ProMMise)
- Escalating doses of Forimtamig (RO7425781) for relapsed and/or refractory myeloma
- CID-103 for Relapsed and/or Refractory Myeloma
- Improving the early detection of myeloma in smouldering myeloma patients (COSMOS)
- Belantamab mafodotin with bortezomib, lenalidomide and dexamethasone for newly diagnosed myeloma (DREAMM 9)
- Adaptive treatment in newly diagnosed myeloma patients not eligible for HDT-SCT (FiTNEss, Myeloma XIV)
- Evaluating patient-based treatment strategies for newly diagnosed myeloma patients (RADAR)
- CCS1477 for the treatment of relapsed/refractory myeloma patients
- bb2121 CAR T-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- Myeloma XII (ACCoRd)
Trial Title:
Ide-cel CAR-T cell treatment with lenalidomide maintenance for newly diagnosed myeloma (KarMMa-9)
Treatments:
Ide-cel (bb2121) (CAR-T cell therapy)
Lenalidomide (Revlimid®)
Fludarabine
Cyclophosphamide
Myeloma stage:
Newly Diagnosed
Trial phase:
III
Summary:
This trial is investigating the effectiveness and tolerability of idecabtagene vicleucel (ide-cel) with lenalidomide (Revlimid®) maintenance treatment compared to lenalidomide maintenance treatment on it’s own, for people with newly diagnosed myeloma who have not had a complete response to high‑dose therapy and stem cell transplantation (HDT-SCT).
CAR-T cell treatment is a type of immunotherapy and uses the body’s own immune system to kill myeloma cells. CAR-T cells are made by taking T-cells (a type of immune cell) from the patient’s blood and genetically modifying them in a laboratory, so they are much better at finding and killing myeloma cells. The new CAR-T cells are then given back to the patient. The CAR-T cells can then find and kill the myeloma cells.
Lenalidomide is an immunomodulatory drug (IMiD) that works by affecting the body’s immune system. Maintenance treatment in myeloma is treatment given long‑term after the main treatment has finished and is intended to lengthen remission time and delay disease progression.
Locations:
Queen Elizabeth Hospital, Birmingham
Who can enter the study?:
Newly diagnosed myeloma patients who have had high-dose therapy and autologous stem cell transplantation (HDT-SCT) for myeloma. Patients must have had at least a partial response (PR) or very good partial response (VGPR) to treatment and had their stem cell transplant 80-120 days ago.
High-dose (induction) therapy before transplant must have included 4-6 cycles of therapy that included a proteosome inhibitor and immunomodulatory agent (IMiD) with or without a CD38 monoclonal antibody.
What's involved?:
Patients will be randomised to receive either ide-cel CAR-T treatment with lenalidomide maintainence, fludarabine (Fludara®) and cyclophosphamide or lenalidomide maintenance treatment alone.
Patients will be required to attend outpatient clinics for regular check-ups and tests.
Patients will be followed up for up to 5 years.
Clinical Information
(for Medical Professionals):
A randomized, open-label, phase 3 trial to compare the efficacy and safety of idecabtagene vicleucel With lenalidomide maintenance versus lenalidomide maintenance therapy alone in adult participants with newly diagnosed multiple myeloma who have suboptimal response after autologous stem cell transplantation (KarMMa-9).
For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk